Brind.
  1. Innovent Biologics partnered with Spero Therapeutics Inc. to advance the development of IBI355.

HCRx buys into Utebzi milestones and royalties, GSK grants exclusive license for Utebzi, and Spero in-licenses SP001 from Innovent Biologics.

1 report, 1 independent Updated Jul 14
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

HCRx buys into Utebzi milestones and royalties, GSK grants exclusive license for Utebzi, and Spero in-licenses SP001 from Innovent Biologics.

Who's involved

What this event is mainly about
GSKInnovent Biologics

How it developed

Newest first. Tap a step to see who reported it.
  1. GSK out-licensed the commercialization rights for Spero Therapeutics' first drug.Sub-event
  2. Spero Therapeutics in-licenses SP001 from Innovent Biologics, updating their partnership.1 source

Keep exploring

Part of

Innovent Biologics partnered with Spero Therapeutics Inc. to advance the development of IBI355. All 1 developments

The entities involved

  • GSK

    British multinational pharmaceutical and biotechnology company

    Nothing else this week.

  • Innovent Biologics

    Chinese Biopharmaceutical Company

    Nothing else this week.

Coverage

Newest first; wire copies grouped